Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Deep Liver Phenotyping and Immunology Study (DELPHI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04946773
Recruitment Status : Recruiting
First Posted : July 1, 2021
Last Update Posted : July 1, 2021
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide. It is known that most of these cancers occur in patients who already have a liver condition. Despite close monitoring of many patients who have liver disease with regular ultrasound scans, HCC and cholangiocarcinoma are often discovered at a late stage. This is because they rarely cause symptoms until they have reached an advanced stage. Early identification of these cancers would enable more patients to have curative treatments such as surgery or liver transplantation.

The investigators want to collect blood and urine samples as well as small samples of cells directly from the liver. In some cases this will be done using a technique called liver fine needle aspiration. This technique is low risk and has been successfully used in other studies. The investigators will compare samples from patients with cancer to those of patients with other diseases of the liver who are at risk of developing cancer in the future.

The investigators aim to detect changes in the liver, blood, urine and/or bile of patients who have liver conditions that could tell us their risk of a future cancer. These changes could be in the types of white blood cells found within the liver, or, they may be in products secreted by liver cells. In the latter case the liver cells may release small pieces of their DNA that could be detected in the blood. When liver cells are dysfunctional, they may also change the types of metabolic products that they produce, and the investigators may be able to detect these changes in the urine or bile.


Condition or disease
Hepatocellular Carcinoma Cholangiocarcinoma

Detailed Description:

The purpose of this study is to perform a characterisation of the cancer predisposing 'field effect' that is associated with hepatic & hepato-biliary malignancy, and, to identify minimally invasive biomarkers that may detect this field effect. This will be achieved through collection of patient samples (Tissue/Blood/Urine/Bile). Comparisons will then be made between patients with hepatic & hepatobiliary cancer and patients with chronic liver disease and also longitudinally in individual patients who either develop or are cured of hepatic & hepato-biliary malignancy during the study. The investigators hope to exploit this knowledge to develop novel biomarker candidates that may ultimately form inputs to a multi-parametric early cancer detection model. The study aims are:

  1. Develop a cohort of patients with HCC, cholangiocarcinoma or liver metastases and a cohort of chronic liver disease patients representing all the commonly encountered aetiologies (viral, metabolic, autoimmune and alcohol related liver disease).
  2. Collect samples from directly within the non-cancerous liver (FNA liver/biopsy/ablation/resection specimens), blood and urine in addition tumour tissue (resection/biopsy/ablation), bile and bile duct brushings.
  3. Flow cytometric & molecular biologic analysis of tissue and peripheral blood and bile.
  4. Transcriptomic analysis of cell populations in liver and blood.
  5. Genetic & molecular biologic analysis of hepatic and immune cells and secreted products.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 15 Years
Official Title: Deep Liver Phenotyping and Immunology Study
Actual Study Start Date : March 12, 2021
Estimated Primary Completion Date : October 31, 2040
Estimated Study Completion Date : October 31, 2040

Resource links provided by the National Library of Medicine


Group/Cohort
Malignancy Cohort
Patients with hepatic or hepatobiliary malignancy at enrolment
Control Cohort
Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment



Primary Outcome Measures :
  1. Defining the differences in the hepatic immune microenvironment that are associated with malignancy. [ Time Frame: At study enrolment ]
    Between group comparison of intra-hepatic and peripheral immune cell populations determined by single cell RNA sequencing.


Secondary Outcome Measures :
  1. Long-term follow-up of patient cohorts [ Time Frame: 15 years ]
    Passive data collection on occurrence or recurrence of hepatic & hepatobiliary malignancy

  2. Identify candidate biomarkers [ Time Frame: 15 years ]
    Biomarkers for for early detection or early diagnosis of hepatic & hepatobiliary malignancy


Other Outcome Measures:
  1. Fine needle aspiration in cirrhosis: safety [ Time Frame: 5 years ]
    Monitoring the safety of liver fine needle aspiration as a research procedure in cirrhotic patient cohorts. Determined through documentation of adverse events.

  2. Fine needle aspiration in cirrhosis: Tolerability [ Time Frame: 5 years ]
    Monitoring the tolerability of liver fine needle aspiration as a research procedure in cirrhotic patient cohorts. Evaluation of subjective post-procedure pain scores.


Biospecimen Retention:   Samples With DNA
Tissue, blood, urine & bile


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hepatology patients treated at a single hospital trust.
Criteria

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years to 75 years.

Malignancy Cohort: extra inclusion criteria - Diagnosed with a malignancy or with clinical suspicion of a malignancy affecting the Liver or Biliary Tree.

Control cohort: extra inclusion criteria

- Patients with confirmed chronic non-malignant hepatobiliary disease.

Additional Inclusion Criteria for Patients Undergoing optional Liver FNA

  • Willing to undergo ultrasound guided liver FNA (unless specific contra-indications to the procedure apply).
  • Has undergone appropriate clinical imaging of the upper abdomen (US/CT/MRI) within the last 12 months.
  • Full blood count (FBC) and coagulation profile (Coag) checked within 30 days prior to FNA procedure (Baseline Visit).

Exclusion Criteria:

  • Unable to consent.
  • Pregnancy.
  • Any concern by the investigator regarding the safe participation of the patient in the study; or investigator's consideration, for any other reason, that a patient is inappropriate for participation in the study.

Additional Exclusion Criteria for Patients Undergoing optional Liver FNA (These criteria will exclude a patient from having FNA as part of the study)

  • Significant comorbid medical condition(s) which may in the opinion of the investigator increase the risk of an FNA Liver.
  • Coagulopathy - International Normalized Ratio (INR) >1.3, Prothrombin Time (PT) >16 seconds, Platelet count <100 x 10^3/L.
  • Known bleeding disorder (e.g. Haemophilia).
  • Current use of an oral/injectable anticoagulant medication.
  • Current use of an oral antiplatelet agent.
  • The presence of ascites.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04946773


Contacts
Layout table for location contacts
Contact: Rory J Peters +441865220077 Rory.peters@ndm.ox.ac.uk

Locations
Layout table for location information
United Kingdom
John Radcliffe Hospital Recruiting
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Contact: Rory J Peters    +441865220077    Rory.peters@ndm.ox.ac.uk   
Sponsors and Collaborators
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Rory J Peters University of Oxford
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT04946773    
Other Study ID Numbers: 264839
C2195/A27431 ( Other Grant/Funding Number: Cancer Research UK )
CA30358/A29725 ( Other Grant/Funding Number: Cancer Research UK )
First Posted: July 1, 2021    Key Record Dates
Last Update Posted: July 1, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Oxford:
Early Detection
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangiocarcinoma
Carcinoma, Hepatocellular
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases